Pharmacoeconomic review report: Risankizumab (Skyrizi) (AbbVie)
Risankizumab is a humanized immunoglobulin G1 monoclonal antibody with an indication for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Risankizumab is available as a solution for injection in a single-use, pre-filled...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
June 2019, 2019
|
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references